Review describes the process of updating the global evidence-based consensus guideline on management of desmoid tumor, a rare and locally aggressive fibroblastic proliferation characterized by a variable and often unpredictable clinical course. ja.ma/4bbPw8b

It’s out! This guideline JAMA Oncology #desmoid reflects our multidisciplinary global collaboration, highlights new treatment strategies &importance of quality of life. Thanks Bernd Kasper, Alessandro Gronchi, pts, all. Current Management of Desmoid Tumors: A Review. pubmed.ncbi.nlm.nih.gov/38900421/

Such a pleasure having you Ursula Sansom-Daly, PhD and hearing about all your interesting research projects with such a passion for #AYA and #palliative and supportive care!

Grateful to chair the board of EORTC for another 2 years with so many excellent and highly motivated board members. 5 New Taskforces: ADC, MRD, Radioligands, RARE and Elderly will direct a new clinical trials agenda. 1000 young & early career investigators willing to contribute!

Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine. This multidisciplinary review of #sarcoma management is a great resource for oncology trainees. Read the free review! acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca…

A moment of calm to ease you into the weekend ✨ Here’s the wonderful MILOŠ playing Rodrigo’s Concierto de Aranjuez in rehearsals last year, conducted by Karen Kamensek. ❤️

July #sarcomaawarenessmonth. E. Holthuis Olga Husson Improving Diagnosis and Care for Patients With Sarcoma: Do Real-World General Practitioners Data and Prospective Data Collections Have a Place Next to Clinical Trials? | JCO Clinical Cancer Informatics ascopubs.org/doi/10.1200/CC…

Primary delay #sarcoma diagnosis is patient & doctor related. No surprise: sarcomas are rare. Our first study Olga Husson with GPs and our PhD student Emily Holthuis. The prediagnostic general practitioner care of sarcoma patients: A real-world data study pubmed.ncbi.nlm.nih.gov/38946219/

📢Join the EORTC HQ team in #Brussels for one-year and become our next #QualityOfLife research fellow. This position is focused on patient-reported outcomes in #cancer #ClinicalTrials. Apply now: eortc.org/job/fellowship… #CancerResearch #Oncology #Fellowship #WorkWithUs #Vacancy

Another example of the added value of WGS in #sarcoma Introduction and impact of routine whole genome sequencing in the diagnosis and management of sarcoma. pubmed.ncbi.nlm.nih.gov/38997407/

Thanks to you Stella Kyriakides for your great leadership of the #EUCancerPlan & for listening to needs & concerns of cancer patients & professionals across Europe. This week in Strasbourg, we’ve been overwhelmed with support from MEPs for the Plan. Thank you Stella!@EuropeanCancer

📅Wat zijn de nieuwste inzichten over immuuntherapie in de behandeling van kanker? Wat betekent dit voor huisartsen? Internist-oncoloog Sebastian Klobuch vertelt over de mogelijkheden van immuuntherapie tijdens het Huisartsensymposium. Meer informatie ➡️ avl.nl/agenda/2024/hu…

Children (0-17) had/have better 5yr Rel Surv than AYA(18-39 yr). 5yr RS improved over time( 1990-2018) Ch 56.3-70.2%; AYA 36.8-53.3% The survival disparity between children and adolescents and young adults (AYAs) with Ewing sarcoma in the Netherlan… pubmed.ncbi.nlm.nih.gov/39018631/

george demetri Very sad to hear about the loss of Chris Fletcher. He was an extraordinary pathologist, who made seminal advances in the diagnosis of sarcomas. My condolences to his colleagues Dana-Farber and to his many mentees and friends in the sarcoma community around the world.

Congratulations Sandra P D'Angelo, MD and all involved. This is a transformative achievement, which we need so much for our patients!

Lung cancer is 15x more common in Li-Fraumeni syndrome individuals from a study. Early detection via whole body MRI is promising. Maximal lung-sparing resection, akin to metastasectomy, prioritizes lung capacity in the context of future cancer risks. ja.ma/3SVk5ZR

🌟Join us at #ENASymp24 on 23-25/10/2024 in Barcelona to learn more about drug development, translational research, and molecular target validation, and benefit from this great networking opportunity! 👉event.eortc.org/ena2024/regist… AACR, National Cancer Institute, Elisabeth de Vries, Tim Greten

Patients who want to directly contribute to cancer research face several barriers. Our Journal of Clinical Oncology commentary, co-authored by leaders of the PE-CGS National Cancer Institute, offers solutions to address them: bit.ly/PECGS-JCO Dana-Farber Dana-Farber News Broad Institute Count Me In

Very grateful to The Lancet Oncology to make this AYA cancer Commission happen. This in person meeting in Toronto was so instrumental to get to know each other (better) and to better define the topics and the work that needs to be done. Great multidisciplinary group in good spirits!

Don't miss you meet Common Sense Oncology at #ESMO24 🇪🇸 ! WinetteVanDerGraaf 🧑🏼‍⚕️ Rodrigo Lastra del Prado 👨🏻‍⚕️ Bishal Gyawali 🦸🏻‍♂️& me🕺🏻 Can't wait to meet you all around!! 🫂🤗🤗